Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jovin J Y Choo"'
Publikováno v:
Expert Review of Vaccines, Vol 0, Iss 0 (2023)
Introduction Microneedles are emerging as a promising technology for vaccine delivery, with numerous advantages over traditional needle and syringe methods. Preclinical studies have demonstrated the effectiveness of MAPs in inducing robust immune res
Externí odkaz:
https://doaj.org/article/4ecb781fea1a40208370ae0a080e5da2
Autor:
Ariel Isaacs, Alberto A. Amarilla, Julio Aguado, Naphak Modhiran, Eduardo A. Albornoz, Alireza A. Baradar, Christopher L. D. McMillan, Jovin J. Y. Choo, Adi Idris, Aroon Supramaniam, Nigel A. J. McMillan, David A. Muller, Paul R. Young, Trent M. Woodruff, Ernst J. Wolvetang, Keith J. Chappell, Daniel Watterson
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Since the start of the COVID-19 pandemic, multiple waves of SARS-CoV-2 variants have emerged. Of particular concern is the omicron variant, which harbors 28 mutations in the spike glycoprotein receptor binding and N-terminal domains relative to the a
Externí odkaz:
https://doaj.org/article/4cb5d30fc1704d60b97006877192104a
Autor:
Jovin J. Y. Choo, Laura J. Vet, Christopher L. D. McMillan, Jessica J. Harrison, Connor A. P. Scott, Alexandra C. I. Depelsenaire, Germain J. P. Fernando, Daniel Watterson, Roy A. Hall, Paul R. Young, Jody Hobson-Peters, David A. Muller
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-10 (2021)
Abstract Dengue viruses (DENV) cause an estimated 390 million infections globally. With no dengue-specific therapeutic treatment currently available, vaccination is the most promising strategy for its control. A wide range of DENV vaccines are in dev
Externí odkaz:
https://doaj.org/article/3a288fab6e9c432db1197a1c7a39ffd8
Autor:
Christopher L. D. McMillan, Armira Azuar, Jovin J. Y. Choo, Naphak Modhiran, Alberto A. Amarilla, Ariel Isaacs, Kate E. Honeyman, Stacey T. M. Cheung, Benjamin Liang, Maria J. Wurm, Paco Pino, Joeri Kint, Germain J. P. Fernando, Michael J. Landsberg, Alexander A. Khromykh, Jody Hobson-Peters, Daniel Watterson, Paul R. Young, David A. Muller
Publikováno v:
Vaccines, Vol 10, Iss 4, p 578 (2022)
The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to disrupt essential health services in 90 percent of countries today. The spike (S) protein found on the surface of the causative agent, the SARS-CoV-2 virus, has been the prime targ
Externí odkaz:
https://doaj.org/article/047b2bd3483b4cd9b6da0a66f2543ada
Autor:
Jovin J. Y. Choo, Christopher L. D. McMillan, Germain J. P. Fernando, Roy A. Hall, Paul R. Young, Jody Hobson-Peters, David A. Muller
Publikováno v:
Vaccines, Vol 9, Iss 11, p 1301 (2021)
Alternative delivery systems such as the high-density microarray patch (HD-MAP) are being widely explored due to the variety of benefits they offer over traditional vaccine delivery methods. As vaccines are dry coated onto the HD-MAP, there is a need
Externí odkaz:
https://doaj.org/article/c3781db295914ec3b1fdb0bb6b7d13c9
Autor:
Alberto A. Amarilla, David A. Muller, Naphak Modhiran, Nigel A.J. McMillan, Aroon Supramaniam, Ariel Isaacs, Jovin J Y Choo, Helle Bielefeldt-Ohmann, Christopher L. D. McMillan, Adi Idris, Gabrielle E. Kelly, Michael J. Landsberg, Germain J. P. Fernando, Stacey T. M. Cheung, Daniel Watterson, Benjamin Liang, Armira Azuar, Paul R. Young, Alexander A. Khromykh, Dhruba Acharya
Publikováno v:
Science Advances
Description
Delivery of a SARS-CoV-2 vaccine to the skin of mice via microarray patches provides complete protection from challenge.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 160 million people and
Delivery of a SARS-CoV-2 vaccine to the skin of mice via microarray patches provides complete protection from challenge.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 160 million people and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2baf8da41a037cbeae0d9bacff413cb
https://doi.org/10.1126/sciadv.abj8065
https://doi.org/10.1126/sciadv.abj8065
Autor:
Christopher L. D. McMillan, Armira Azuar, Helle Bielefeldt-Ohmann, Gabrielle E. Kelly, Germain J. P. Fernando, David A. Muller, Ariel Isaacs, Daniel Watterson, Paul R. Young, Alberto A. Amarilla, Michael J. Landsberg, Nigel A.J. McMillan, Alexander A. Khromykh, Naphak Modhiran, Benjamin Liang, Stacey T. M. Cheung, Jovin J Y Choo, Dhruba Acharya, Adi Idris, Aroon Supramaniam
SARS-CoV-2 has infected over 160 million people and resulted in more than 3.3 million deaths, and we still face many challenges in the rollout of vaccines. Here, we use the high-density microarray patch to deliver a SARS-CoV-2 spike subunit vaccine d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81b1d6149fad1e334031f3cdabd3ac3c
https://doi.org/10.1101/2021.05.30.446357
https://doi.org/10.1101/2021.05.30.446357
Autor:
David A. Muller, Paul R. Young, Jessica J. Harrison, Connor A. P. Scott, Daniel Watterson, Jovin J Y Choo, Jody Hobson-Peters, Alexandra C. I. Depelsenaire, Laura J. Vet, Germain J. P. Fernando, Christopher L. D. McMillan, Roy A. Hall
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-10 (2021)
NPJ Vaccines
NPJ Vaccines
Dengue viruses (DENV) cause an estimated 390 million infections globally. With no dengue-specific therapeutic treatment currently available, vaccination is the most promising strategy for its control. A wide range of DENV vaccines are in development,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6c712fe95c4721622fcb8b5ab7ef6a6
https://doi.org/10.1038/s41541-021-00328-1
https://doi.org/10.1038/s41541-021-00328-1